| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abstracts from the 5th International Porto Congress of Multiple Sclerosis
|
Sá, Maria José
|
|
|
8 |
Suppl 2 |
p. 1-31
|
artikel
|
| 2 |
Abstracts from the 5th International Porto Congress of Multiple Sclerosis
|
Sá, Maria José
|
|
|
8 |
Suppl 2 |
p. 1-31
|
artikel
|
| 3 |
Advance in Plasma AD Core Biomarker Development: Current Findings from Immunomagnetic Reduction-Based SQUID Technology
|
Lue, Lih-Fen
|
|
|
8 |
Suppl 2 |
p. 95-111
|
artikel
|
| 4 |
Advance in Plasma AD Core Biomarker Development: Current Findings from Immunomagnetic Reduction-Based SQUID Technology
|
Lue, Lih-Fen
|
|
|
8 |
Suppl 2 |
p. 95-111
|
artikel
|
| 5 |
A Novel Dual-Frequency Deep Brain Stimulation Paradigm for Parkinson’s Disease
|
Karl, Jessica A.
|
|
|
8 |
Suppl 2 |
p. 483-489
|
artikel
|
| 6 |
A Novel Dual-Frequency Deep Brain Stimulation Paradigm for Parkinson’s Disease
|
Karl, Jessica A.
|
|
|
8 |
Suppl 2 |
p. 483-489
|
artikel
|
| 7 |
A Videogame-Based Digital Therapeutic to Improve Processing Speed in People with Multiple Sclerosis: A Feasibility Study
|
Bove, Riley M.
|
|
2018
|
8 |
Suppl 2 |
p. 135-145
|
artikel
|
| 8 |
Bioavailability and Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets in Healthy Volunteers: Results from Three Randomized, Crossover, Open-Label, Phase 1 Studies
|
deVries, Tina
|
|
|
8 |
Suppl 2 |
p. 449-460
|
artikel
|
| 9 |
Bioavailability and Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets in Healthy Volunteers: Results from Three Randomized, Crossover, Open-Label, Phase 1 Studies
|
deVries, Tina
|
|
|
8 |
Suppl 2 |
p. 449-460
|
artikel
|
| 10 |
Cerebrolysin as a New Treatment Option for Post-Stroke Spasticity: Patient and Physician Perspectives
|
Chemer, Nataliia
|
|
2019
|
8 |
Suppl 2 |
p. 25-27
|
artikel
|
| 11 |
Effectiveness and Safety/Tolerability of Eslicarbazepine Acetate in Epilepsy Patients Aged ≥ 60 Versus < 60 Years: A Subanalysis from the Euro-Esli Study
|
Lawthom, Charlotte
|
|
|
8 |
Suppl 2 |
p. 491-504
|
artikel
|
| 12 |
Effect of Anodal tDCS on Articulatory Accuracy, Word Production, and Syllable Repetition in Subjects with Aphasia: A Crossover, Double-Blinded, Sham-Controlled Trial
|
Vila-Nova, Camila
|
|
|
8 |
Suppl 2 |
p. 411-424
|
artikel
|
| 13 |
Effect of Anodal tDCS on Articulatory Accuracy, Word Production, and Syllable Repetition in Subjects with Aphasia: A Crossover, Double-Blinded, Sham-Controlled Trial
|
Vila-Nova, Camila
|
|
|
8 |
Suppl 2 |
p. 411-424
|
artikel
|
| 14 |
Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)
|
Okai, Annette F.
|
|
|
8 |
Suppl 2 |
p. 367-381
|
artikel
|
| 15 |
Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)
|
Okai, Annette F.
|
|
|
8 |
Suppl 2 |
p. 367-381
|
artikel
|
| 16 |
Late Onset of Neuromyelitis Optica Spectrum Disorders
|
Fragoso, Yara Dadalti
|
|
|
8 |
Suppl 2 |
p. 477-482
|
artikel
|
| 17 |
Late Onset of Neuromyelitis Optica Spectrum Disorders
|
Fragoso, Yara Dadalti
|
|
|
8 |
Suppl 2 |
p. 477-482
|
artikel
|
| 18 |
Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing–Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMS II Trials
|
Ghezzi, Angelo
|
|
|
8 |
Suppl 2 |
p. 461-475
|
artikel
|
| 19 |
Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing–Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMS II Trials
|
Ghezzi, Angelo
|
|
|
8 |
Suppl 2 |
p. 461-475
|
artikel
|
| 20 |
Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing–Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMS II Trials
|
Ghezzi, Angelo
|
|
|
8 |
Suppl 2 |
p. 461-475
|
artikel
|
| 21 |
Modeling the Choice Between Risperidone Long-Acting Injectable and Generic Risperidone from the Perspective of a Japanese Hospital
|
Nakamura, Yusuke
|
|
|
8 |
Suppl 2 |
p. 433-447
|
artikel
|
| 22 |
Modeling the Choice Between Risperidone Long-Acting Injectable and Generic Risperidone from the Perspective of a Japanese Hospital
|
Nakamura, Yusuke
|
|
|
8 |
Suppl 2 |
p. 433-447
|
artikel
|
| 23 |
Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis: Management Strategies to Improve Persistence on Treatment and Patient Outcomes
|
Min, Jinny
|
|
2019
|
8 |
Suppl 2 |
p. 109-119
|
artikel
|
| 24 |
Risperdal® CONSTA® Needle Detachment. Incidence Rates Before and After Kit Redesign: A Retrospective Study using Electronic Health Records and Natural Language Processing in the Department of Veterans Affairs
|
Wilcox, Marsha A.
|
|
2019
|
8 |
Suppl 2 |
p. 95-108
|
artikel
|
| 25 |
Treatment Effectiveness for Resolution of Multiple Sclerosis Relapse in a US Health Plan Population
|
Nazareth, Tara
|
|
|
8 |
Suppl 2 |
p. 383-395
|
artikel
|
| 26 |
Treatment Effectiveness for Resolution of Multiple Sclerosis Relapse in a US Health Plan Population
|
Nazareth, Tara
|
|
|
8 |
Suppl 2 |
p. 383-395
|
artikel
|
| 27 |
Treatment Patterns, Healthcare Resource Utilization, and Costs Among Medicare Patients with Multiple Sclerosis in Relation to Disease-Modifying Therapy and Corticosteroid Treatment
|
Sanchirico, Marie
|
|
2018
|
8 |
Suppl 2 |
p. 121-133
|
artikel
|
Tijdschrift beschrijving